Cantor Fitzgerald Starts Phathom Pharmaceuticals (PHAT) at Overweight
Tweet
Share
E-mailGet Alerts PHAT Hot Sheet
Price: $9.11 -0.65%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 16 | New: 9
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 16 | New: 9
Join SI Premium – FREE
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Overweight rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.
Shares of Phathom Pharmaceuticals closed at $5.62 yesterday.
You May Also Be Interested In
- Lake Street Starts RF Industries Ltd. (RFIL) at Buy
- Goldman Sachs Starts Vail Resorts (MTN) at Sell
- Morgan Stanley Starts Achieve Life Sciences (ACHV) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
